Nasdaq
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. The company is headquartered in Newtown, Pennsylvania.
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $661,000.00 | $522,000.00 | $787,000.00 | $644,000.00 | $520,000.00 | $6.0M |
| Gross profit | $273,000.00 | $224,000.00 | $324,000.00 | $61,000.00 | -$62,000.00 | $5.5M |
| Operating income | -$14.4M | -$18.1M | -$15.5M | -$12.4M | -$13.9M | -$243.8M |
| Net income | -$14.1M | -$18.1M | -$14.1M | -$8.9M | -$11.7M | -$40.9M |
| Diluted EPS | -$11.80 | -$7.38 | -$52.13 | -$14.56 | -$3,282.26 | -$1.85 |
| Operating cash flow | -$11.7M | -$13.4M | -$14.3M | -$10.4M | -$11.0M | -$16.5M |
| Free cash flow | -$11.8M | -$13.4M | -$14.3M | -$10.4M | -$11.0M | — |
| Gross margin | 41.3% | 42.9% | 41.2% | 9.5% | -11.9% | 91.7% |
| Operating margin | -2176.4% | -3475.5% | -1971.5% | -1929.8% | -2673.7% | -4052.5% |
| Net margin | -2137.7% | -3473.6% | -1788.1% | -1382.0% | -2250.0% | -679.7% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $182,000.00 | $51,000.00 | $152,000.00 | $49,000.00 | $43,000.00 | $697,000.00 | $5.2M | $3.6M |
| Gross profit | $64,000.00 | -$136,000.00 | -$2,000.00 | -$72,000.00 | -$53,000.00 | $594,000.00 | $5.0M | $3.4M |
| Operating income | -$3.3M | -$4.1M | -$3.1M | -$4.0M | -$3.3M | -$35.5M | -$201.1M | -$99.6M |
| Net income | -$1.6M | -$3.7M | -$3.9M | -$3.8M | -$9.8M | -$352.8M | $325.5M | -$99.8M |
| Diluted EPS | -$485.30 | -$744.35 | -$2,049.53 | -$382.29 | -$79.73 | -$32.89 | $493.06 | -$1.30 |
| Operating cash flow | -$2.9M | -$2.8M | -$2.4M | -$3.5M | -$2.8M | -$4.0M | -$6.2M | -$4.8M |
| Free cash flow | -$2.9M | -$2.8M | -$2.4M | — | — | — | — | — |
| Gross margin | 35.2% | -266.7% | -1.3% | -146.9% | -123.3% | 85.2% | 96.6% | 95.0% |
| Operating margin | -1796.7% | -7980.4% | -2070.4% | -8185.7% | -7725.6% | -5086.1% | -3845.8% | -2751.1% |
| Net margin | -885.7% | -7227.5% | -2556.6% | -7832.7% | -22867.4% | -50612.3% | 6226.8% | -2756.1% |
Consensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-02 | Jiang Cosmo Yi | Tax withholding | 610 | $1.65 | $1,006.50 | filing |
| 2026-06-02 | Jiang Cosmo Yi | Option exercise | 1,005,040 | $0.00 | $1,005.04 | filing |
| 2026-05-21 | Mello Sergio | Award | 6,360 | $0.00 | $0.00 | filing |
| 2026-05-21 | Lee Michel Kai Tai | Award | 6,360 | $0.00 | $0.00 | filing |
| 2026-05-21 | STRAW EDWARD M | Award | 6,360 | $0.00 | $0.00 | filing |
| 2026-05-21 | Walter Blane | Award | 6,360 | $0.00 | $0.00 | filing |
| 2026-05-11 | Fusion Summer Ltd | J | 1,453,277 | $0.00 | $0.00 | filing |
| 2026-05-11 | Summer Wisdom Holdings Ltd | J | 1,453,277 | $0.00 | $0.00 | filing |
| 2026-03-31 | STRAW EDWARD M | Award | 2,180 | $0.00 | $0.00 | filing |
| 2026-03-31 | Walter Blane | Award | 2,180 | $0.00 | $0.00 | filing |
| 2026-03-31 | Perkins Sherrie L | Award | 2,180 | $0.00 | $0.00 | filing |
| 2026-03-31 | BUCKMAN PAUL | Award | 2,180 | $0.00 | $0.00 | filing |
| 2026-03-31 | STRAW EDWARD M | Award | 2,180 | $0.00 | $0.00 | filing |
| 2026-03-31 | Walter Blane | Award | 2,180 | $0.00 | $0.00 | filing |
| 2025-09-18 | Chee Choon Wee· Executive Chairman | Option exercise | 1,109,118 | $0.00 | $0.00 | filing |
Latest 15 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.